CARDIOVASCULAR
hamburger

Only Jot Dx ICM from Abbott puts you in complete control

Jot Dx™ Insertable Cardiac Monitor (ICM) is the latest medical technology advancement only from Abbott that helps restore people’s health so they can get back to living their best lives, faster.

Remote monitoring empowers you to make timely healthcare decisions if needed. Our SyncUP™ service helps ensure your Jot Dx ICM implanted patients are properly connected to the myMerlin™ mobile app so that data is automatically sent to your clinic.


Decrease Your Data Burden,
Increase Control


 

Focus your diagnostic data

Choose to view three key episodes* for a patient or facility.



Decrease your data burden on average by

With Key Episodes turned on and Jot Dx ICM pause algorithm improvements

63%
63%

Potential Staff Time Savings From Reduced Data Burden

All patients2

Hours/year reduction

120 Clinic Personnel
36 Electrophysiologists

Top 25th percentile patients2

Hours/year reduction

300 Clinic Personnel
96 Electrophysiologists

Manage With Flexibility to get all Episodes

For hard-to-detect arrhythmias you can toggle to view all episodes for a specific patient, rather than three key episodes. You can also view all episodes facility-wide.

Toggle Episodes

Get Episode Data Unique to each arrhythmia type

Key episodes are uniquely programmed to evaluate each arrhythmia differently: AFib, Tachy, Brady and Pause each have a novel set of evaluation criteria that make up the three key episodes. This ensures you receive the most insightful data based on arrhythmia type.

Better selection criteria sets Jot Dx ICM apart from others that use a standard set of criteria for all types.

Arrhythmia Types

Diagnose with Confidence

Even with three key episodes turned on, there is no loss of accuracy, and virtually no delay-to-diagnosis.2

Arrhythmia Diagnosis

Detect With Accuracy

With Sharpsense Technology, Greater P-Wave and R-Wave Visibility Detect True Episodes.

Jot Dx ICM with SharpSense™ technology improves accuracy of all episodes by harnessing the power of extra discriminators to confirm or reject detections – significantly improving the accuracy of Atrial Fibrillation, Bradycardia and Pause detected episodes.

Episode Algorithm

Relative Sensitivity

Bradycardia 99.9%
Pause 99.6%
AFib 98.6%


overall reduction in false positives
5

Retrospective analysis of a Global Registry demonstrates SharpSense™ technology significantly reduces false detection of AFib, Bradycardia and Pause episodes.

 97.8% reduction in false positives

References

*Key episodes is a feature of Merlin.net™
**Determined by evaluation of real-world episodes in previously identified devices, using SharpSense™ technology.

  1. EGM Burden Reduction in Jot Dx ICM, Technical Development Report System DOC 90805939 Rev A.
  2. HRS 2021 Poster - Reducing Clinical Review Burden of Insertable Cardiac Monitors In Patients with Frequent Arrhythmia Detections
  3. Medtronic REVEAL LINQ Insertable Cardiac Monitor and Patient Assistant PA96000 Clinical Manual, 2015
  4. Medtronic LINQ II Insertable Cardiac Monitor Clinical Manual, 2020
  5. Piorkowski C, Manyam H, Lakkireddy D, et al. Effectiveness and performance of Confirm Rx SharpSense Technology: A Multi-center Retrospective Analysis. Presented at Asia Pacific Heart Rhythm Society (APHRS); Bangkok, Thailand; Oct 27-29, 2019.

™ Indicates a trademark of the Abbott group of companies.
Indicates a third-party trademark, which is property of its respective owner.

MAT-2108290 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.